Oruka Therapeutics Shares Drop After Disappointing Mid-Stage Trial Data for Plaque Psoriasis Drug
Shares of Oruka Therapeutics (ORKA) declined on Wednesday following updated data from a mid-stage trial for its experimental drug ORKA-001, which targets plaque psoriasis. The company released results after 28 weeks in the EVERLAST-A Phase 2a study but failed to meet expectations. The underwhelming performance of the candidate has raised concerns among investors about Oruka's pipeline and future prospects. Plaque psoriasis is a significant unmet medical need, making successful drug development crucial for companies like Oruka operating in this space. Market reaction was swift as disappointing clinical data often leads to volatility in biotech stocks.
Tickers: $ORKA